Louisiana State Employees Retirement System Acquires New Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Louisiana State Employees Retirement System acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,600 shares of the medical device company’s stock, valued at approximately $964,000.

Other large investors have also bought and sold shares of the company. Eminence Capital LP lifted its holdings in Tandem Diabetes Care by 76.1% in the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after buying an additional 2,372,458 shares during the period. Raymond James & Associates lifted its holdings in Tandem Diabetes Care by 128.5% in the fourth quarter. Raymond James & Associates now owns 91,985 shares of the medical device company’s stock valued at $2,721,000 after buying an additional 51,721 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Tandem Diabetes Care by 4.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 367,011 shares of the medical device company’s stock valued at $7,623,000 after purchasing an additional 16,586 shares in the last quarter. Paradice Investment Management LLC increased its stake in Tandem Diabetes Care by 23.9% in the third quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after purchasing an additional 293,250 shares in the last quarter. Finally, Banque Pictet & Cie SA bought a new stake in Tandem Diabetes Care in the third quarter valued at approximately $2,295,000.

Analysts Set New Price Targets

Several brokerages have commented on TNDM. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. Stifel Nicolaus upped their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Citigroup upped their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $37.27.

Tandem Diabetes Care Stock Up 0.4 %

Shares of TNDM stock opened at $35.12 on Thursday. The firm has a fifty day moving average of $30.51 and a 200-day moving average of $25.18. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. Tandem Diabetes Care, Inc. has a 12-month low of $13.82 and a 12-month high of $40.74. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.21 and a beta of 1.12.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. As a group, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.